EU/3/15/1557

About

On 9 October 2015, orphan designation (EU/3/15/1557) was granted by the European Commission to Desitin Arzneimittel GmbH, Germany, for sirolimus for the treatment of tuberous sclerosis.

Key facts

Active substance
Sirolimus
Disease / condition
Treatment of tuberous sclerosis
Date of first decision
09/10/2015
Outcome
Positive
EU designation number
EU/3/15/1557

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Desitin Arzneimittel GmbH
Weg beim Jäger 214
22335 Hamburg
Germany
Tel. +49 40 591010
Fax +49 40 59101366
E-mail: success@desitin.de

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating